| 17.88 0.25 (1.42%) | 01-24 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.71 | 1-year : | 25.74 |
| Resists | First : | 20.3 | Second : | 22.04 |
| Pivot price | 19.41 |
|||
| Supports | First : | 17.48 | Second : | 14.55 |
| MAs | MA(5) : | 17.87 | MA(20) : | 19.68 |
| MA(100) : | 19.08 |
MA(250) : | 23.05 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.9 | D(3) : | 8.9 |
| RSI | RSI(14): 38.7 | |||
| 52-week | High : | 32.34 | Low : | 16.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRY ] has closed above bottom band by 22.6%. Bollinger Bands are 66.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Wed, 19 Jan 2022
CryoLife announces corporate rebranding and changes name to Artivion - Vascular News
Tue, 18 Jan 2022
CryoLife announces corporate rebrand, changes name to Artivion - Mass Device
Tue, 18 Jan 2022
CryoLife Announces Corporate Rebranding and Changes Name to Artivion - PR Newswire
Tue, 15 May 2012
CryoLife's CEO Discusses Acquisition of Hemosphere, Inc. Conference (Transcript) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 39 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 83.7 (%) |
| Shares Short | 3,470 (K) |
| Shares Short P.Month | 3,420 (K) |
| EPS | 0.03 |
| EPS Est Next Qtrly | 0.11 |
| EPS Est This Year | 0.41 |
| EPS Est Next Year | 0.5 |
| Book Value (p.s.) | 7.92 |
| Profit Margin | 0.6 % |
| Operating Margin | 4.5 % |
| Return on Assets (ttm) | 1 % |
| Return on Equity (ttm) | 0.5 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 4.26 |
| Sales Per Share | 7.3 |
| EBITDA (p.s.) | 0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 2 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 447 |
| PEG Ratio | 449.5 |
| Price to Book value | 2.25 |
| Price to Sales | 2.44 |
| Price to Cash Flow | 327.07 |
| Dividend | 0.02 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | 2015-12-17 |
| Ex-Dividend Date | 2015-12-08 |
|
|
|
|
|
|
|
|
|